| Species |
Human |
| Protein Construction |
TSLP (R127A, R130A) [Tyr29-Gln159(R127A,R130A)]
Accession # Q969D9-1 |
His |
Avi |
| N-term |
|
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Biological Activity |
Measured by its binding ability in a functional ELISA. Immobilized TSLP (R127A, R130A), His & Avi, Human at 2μg/ml (100μl/Well). Dose response curve for Human TSLPR, hFc Tag. Test result was comparable to standard batch. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
17.7 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 25-35 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
Thymic Stromal Lymphopoietin (TSLP) was originally identified as an activity from the conditioned medium of a mouse thymic stromal cell line that promoted the development of B cells. Cytokine that induces the release of T-cell-attracting chemokines from monocytes and, in particular, enhances the maturation of CD11c dendritic cells. Can induce allergic inflammation by directly activating mast cells. |
| Synonyms |
thymic stromal lymphopoietin; TSLP |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
